Your browser doesn't support javascript.
loading
Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.
Zhang, Kai; Hong, Xiaohua; Song, Zhengbo; Xu, Yu; Li, Chengcheng; Wang, Guoqiang; Zhang, Yuzi; Zhao, Xiaochen; Zhao, Zhengyi; Zhao, Jing; Huang, Mengli; Huang, Depei; Qi, Chuang; Gao, Chan; Cai, Shangli; Gu, Feifei; Hu, Yue; Xu, Chunwei; Wang, Wenxian; Lou, Zhenkun; Zhang, Yong; Liu, Li.
Afiliação
  • Zhang K; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China.
  • Hong X; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China.
  • Song Z; Zhejiang Cancer Hospital, Zhejiang, P.R. China.
  • Xu Y; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Li C; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Wang G; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Zhang Y; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Zhao X; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Zhao Z; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Zhao J; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Huang M; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Huang D; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Qi C; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Gao C; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Cai S; The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
  • Gu F; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China.
  • Hu Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China.
  • Xu C; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian, P.R. China.
  • Wang W; Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Zhejiang, P.R. China.
  • Lou Z; Department of Oncology, Mayo Clinic, Rochester, Minnesota. liulixiehe2004@163.com lou.zhenkun@mayo.edu Zhang.Yong@mayo.edu.
  • Zhang Y; Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China. liulixiehe2004@163.com lou.zhenkun@mayo.edu Zhang.Yong@mayo.edu.
  • Liu L; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, P.R. China. liulixiehe2004@163.com lou.zhenkun@mayo.edu Zhang.Yong@mayo.edu.
Clin Cancer Res ; 26(14): 3649-3661, 2020 07 15.
Article em En | MEDLINE | ID: mdl-32241817
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Carcinoma Pulmonar de Células não Pequenas / Receptores Notch / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Carcinoma Pulmonar de Células não Pequenas / Receptores Notch / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Idioma: En Ano de publicação: 2020 Tipo de documento: Article